| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 216 | 2024 | 7045 | 12.410 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 80 | 2024 | 2903 | 9.470 |
Why?
|
| Transplantation Conditioning | 96 | 2024 | 2374 | 6.960 |
Why?
|
| Graft vs Host Disease | 89 | 2024 | 2810 | 6.840 |
Why?
|
| Transplantation, Homologous | 81 | 2024 | 3046 | 3.500 |
Why?
|
| Busulfan | 31 | 2023 | 794 | 3.140 |
Why?
|
| Multiple Myeloma | 43 | 2024 | 2328 | 3.080 |
Why?
|
| Immunotherapy, Adoptive | 40 | 2024 | 1840 | 3.010 |
Why?
|
| Antigens, CD19 | 28 | 2024 | 584 | 2.890 |
Why?
|
| Leukemia, Myeloid, Acute | 66 | 2024 | 7266 | 2.730 |
Why?
|
| Philadelphia Chromosome | 25 | 2024 | 852 | 2.430 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 8 | 2019 | 205 | 2.260 |
Why?
|
| Hepatic Veno-Occlusive Disease | 7 | 2024 | 135 | 2.160 |
Why?
|
| Transplantation, Autologous | 51 | 2024 | 2067 | 2.090 |
Why?
|
| Neoplasm, Residual | 30 | 2024 | 1754 | 2.070 |
Why?
|
| T-Lymphocytes | 29 | 2023 | 3950 | 1.930 |
Why?
|
| Myeloablative Agonists | 17 | 2022 | 388 | 1.850 |
Why?
|
| Cyclophosphamide | 37 | 2024 | 3245 | 1.740 |
Why?
|
| Adult | 206 | 2024 | 82090 | 1.720 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 11 | 2024 | 513 | 1.630 |
Why?
|
| Hematologic Neoplasms | 24 | 2022 | 1956 | 1.590 |
Why?
|
| Recurrence | 50 | 2024 | 4881 | 1.590 |
Why?
|
| Melphalan | 26 | 2023 | 879 | 1.570 |
Why?
|
| Remission Induction | 41 | 2024 | 3657 | 1.560 |
Why?
|
| Cord Blood Stem Cell Transplantation | 15 | 2023 | 372 | 1.530 |
Why?
|
| Humans | 352 | 2024 | 271010 | 1.510 |
Why?
|
| Myelodysplastic Syndromes | 30 | 2024 | 3156 | 1.490 |
Why?
|
| Stem Cell Transplantation | 23 | 2023 | 1418 | 1.420 |
Why?
|
| Receptors, Antigen, T-Cell | 19 | 2023 | 1137 | 1.400 |
Why?
|
| Unrelated Donors | 15 | 2024 | 321 | 1.400 |
Why?
|
| Middle Aged | 195 | 2024 | 90433 | 1.350 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 15 | 2023 | 1739 | 1.320 |
Why?
|
| DNA Transposable Elements | 4 | 2017 | 250 | 1.190 |
Why?
|
| Antibodies, Bispecific | 7 | 2023 | 282 | 1.180 |
Why?
|
| Vidarabine | 25 | 2022 | 1384 | 1.170 |
Why?
|
| Aged | 159 | 2024 | 73460 | 1.170 |
Why?
|
| Young Adult | 87 | 2024 | 22260 | 1.170 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 54 | 2024 | 16689 | 1.170 |
Why?
|
| Allografts | 21 | 2024 | 686 | 1.150 |
Why?
|
| Adolescent | 93 | 2024 | 32777 | 1.150 |
Why?
|
| Salvage Therapy | 15 | 2023 | 2123 | 1.100 |
Why?
|
| Retrospective Studies | 102 | 2024 | 39902 | 1.080 |
Why?
|
| Acute Disease | 20 | 2024 | 2496 | 1.000 |
Why?
|
| Lymphoma, Non-Hodgkin | 7 | 2023 | 1067 | 0.980 |
Why?
|
| Male | 175 | 2024 | 128533 | 0.960 |
Why?
|
| Lymphoma, B-Cell | 7 | 2024 | 929 | 0.950 |
Why?
|
| Disease-Free Survival | 45 | 2021 | 10265 | 0.920 |
Why?
|
| Arabinonucleosides | 7 | 2024 | 470 | 0.920 |
Why?
|
| Vascular Diseases | 2 | 2024 | 235 | 0.900 |
Why?
|
| Antibodies, Monoclonal, Humanized | 11 | 2021 | 3409 | 0.870 |
Why?
|
| Female | 175 | 2024 | 149107 | 0.870 |
Why?
|
| Dexamethasone | 21 | 2024 | 1517 | 0.860 |
Why?
|
| Survival Analysis | 44 | 2023 | 9294 | 0.850 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2024 | 331 | 0.850 |
Why?
|
| Chromosome Aberrations | 14 | 2024 | 2035 | 0.800 |
Why?
|
| Treatment Outcome | 79 | 2024 | 33774 | 0.800 |
Why?
|
| Adenine Nucleotides | 5 | 2016 | 365 | 0.800 |
Why?
|
| Histocompatibility Testing | 13 | 2024 | 487 | 0.790 |
Why?
|
| Lymphocyte Depletion | 5 | 2024 | 316 | 0.760 |
Why?
|
| Whole-Body Irradiation | 4 | 2017 | 323 | 0.750 |
Why?
|
| Antineoplastic Agents, Alkylating | 4 | 2018 | 605 | 0.740 |
Why?
|
| Vincristine | 17 | 2024 | 1583 | 0.730 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 13 | 2021 | 2635 | 0.730 |
Why?
|
| Receptors, Antigen | 5 | 2015 | 68 | 0.710 |
Why?
|
| Survival Rate | 40 | 2024 | 12542 | 0.710 |
Why?
|
| Protein Kinase Inhibitors | 12 | 2024 | 4962 | 0.700 |
Why?
|
| Antigens, Neoplasm | 5 | 2023 | 1580 | 0.650 |
Why?
|
| Antineoplastic Agents | 22 | 2024 | 14623 | 0.610 |
Why?
|
| Cystitis | 2 | 2021 | 109 | 0.610 |
Why?
|
| Fetal Blood | 9 | 2023 | 501 | 0.600 |
Why?
|
| Tacrolimus | 9 | 2023 | 347 | 0.600 |
Why?
|
| Prognosis | 48 | 2024 | 22509 | 0.590 |
Why?
|
| Siblings | 6 | 2024 | 319 | 0.570 |
Why?
|
| Cell- and Tissue-Based Therapy | 12 | 2023 | 384 | 0.560 |
Why?
|
| Central Nervous System Neoplasms | 4 | 2017 | 551 | 0.560 |
Why?
|
| Postoperative Care | 1 | 2020 | 730 | 0.550 |
Why?
|
| Cytomegalovirus Infections | 3 | 2019 | 495 | 0.530 |
Why?
|
| Histocompatibility | 7 | 2018 | 183 | 0.510 |
Why?
|
| Hodgkin Disease | 8 | 2022 | 1485 | 0.510 |
Why?
|
| Genetic Therapy | 5 | 2017 | 1716 | 0.510 |
Why?
|
| Graft Survival | 11 | 2017 | 1083 | 0.500 |
Why?
|
| Burkitt Lymphoma | 4 | 2023 | 350 | 0.480 |
Why?
|
| Neoplasms | 10 | 2024 | 15933 | 0.480 |
Why?
|
| Lymphoma | 7 | 2023 | 1520 | 0.480 |
Why?
|
| Hemorrhage | 2 | 2021 | 727 | 0.480 |
Why?
|
| Antigen-Presenting Cells | 7 | 2016 | 286 | 0.480 |
Why?
|
| Transplantation, Haploidentical | 6 | 2024 | 159 | 0.470 |
Why?
|
| HLA Antigens | 6 | 2024 | 594 | 0.470 |
Why?
|
| B-Lymphocytes | 5 | 2022 | 1424 | 0.460 |
Why?
|
| Follow-Up Studies | 28 | 2024 | 15231 | 0.460 |
Why?
|
| Antibodies, Monoclonal | 6 | 2015 | 4481 | 0.450 |
Why?
|
| Neoplasm Recurrence, Local | 21 | 2023 | 10400 | 0.440 |
Why?
|
| Bone Marrow Transplantation | 7 | 2024 | 1757 | 0.440 |
Why?
|
| Child | 33 | 2023 | 30578 | 0.430 |
Why?
|
| Models, Biological | 3 | 2019 | 3198 | 0.430 |
Why?
|
| Ganciclovir | 1 | 2013 | 194 | 0.430 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2021 | 565 | 0.430 |
Why?
|
| Doxorubicin | 16 | 2024 | 3145 | 0.420 |
Why?
|
| Antigens, CD34 | 5 | 2024 | 640 | 0.410 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 4 | 2018 | 219 | 0.410 |
Why?
|
| Combined Modality Therapy | 19 | 2020 | 9040 | 0.410 |
Why?
|
| Antiviral Agents | 3 | 2016 | 1253 | 0.400 |
Why?
|
| Risk Factors | 28 | 2024 | 17904 | 0.390 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2012 | 92 | 0.390 |
Why?
|
| Fusion Proteins, bcr-abl | 5 | 2023 | 1144 | 0.390 |
Why?
|
| Immunosuppressive Agents | 11 | 2018 | 1432 | 0.380 |
Why?
|
| Protein-Tyrosine Kinases | 8 | 2017 | 1838 | 0.380 |
Why?
|
| Leukemia | 6 | 2017 | 1719 | 0.380 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 3 | 2024 | 1013 | 0.370 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 5 | 2015 | 770 | 0.370 |
Why?
|
| Receptors, Cytokine | 3 | 2023 | 179 | 0.360 |
Why?
|
| Nephritis, Interstitial | 1 | 2011 | 59 | 0.360 |
Why?
|
| Immunotherapy | 5 | 2021 | 3557 | 0.360 |
Why?
|
| BK Virus | 1 | 2011 | 126 | 0.350 |
Why?
|
| Tissue Donors | 4 | 2024 | 821 | 0.350 |
Why?
|
| Neurotoxicity Syndromes | 2 | 2022 | 126 | 0.350 |
Why?
|
| Age Factors | 13 | 2024 | 5468 | 0.340 |
Why?
|
| Incidence | 10 | 2024 | 5829 | 0.340 |
Why?
|
| Mycophenolic Acid | 5 | 2022 | 153 | 0.340 |
Why?
|
| Chromosomes, Human, Pair 11 | 3 | 2019 | 413 | 0.330 |
Why?
|
| Pyridazines | 2 | 2024 | 324 | 0.330 |
Why?
|
| Bone Marrow | 8 | 2021 | 2441 | 0.330 |
Why?
|
| Transposases | 4 | 2013 | 69 | 0.320 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 3 | 2024 | 838 | 0.320 |
Why?
|
| Molecular Targeted Therapy | 2 | 2019 | 2400 | 0.320 |
Why?
|
| Immunologic Factors | 3 | 2021 | 673 | 0.310 |
Why?
|
| Drug Therapy, Combination | 6 | 2022 | 2346 | 0.310 |
Why?
|
| Sulfonamides | 3 | 2024 | 1933 | 0.310 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 5 | 2018 | 271 | 0.300 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2010 | 381 | 0.290 |
Why?
|
| Rituximab | 7 | 2023 | 1594 | 0.290 |
Why?
|
| Maintenance Chemotherapy | 3 | 2024 | 226 | 0.280 |
Why?
|
| Aged, 80 and over | 29 | 2024 | 31050 | 0.280 |
Why?
|
| Biological Products | 4 | 2023 | 319 | 0.270 |
Why?
|
| Donor Selection | 2 | 2024 | 110 | 0.270 |
Why?
|
| Imidazoles | 2 | 2024 | 1066 | 0.270 |
Why?
|
| Translocation, Genetic | 5 | 2023 | 1286 | 0.270 |
Why?
|
| Antimetabolites, Antineoplastic | 3 | 2024 | 1347 | 0.270 |
Why?
|
| Venous Thromboembolism | 2 | 2022 | 376 | 0.270 |
Why?
|
| Child, Preschool | 14 | 2023 | 17068 | 0.270 |
Why?
|
| Receptors, Complement 3b | 2 | 2022 | 20 | 0.260 |
Why?
|
| Asparaginase | 2 | 2024 | 196 | 0.260 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 2 | 2023 | 104 | 0.260 |
Why?
|
| Immunophenotyping | 4 | 2017 | 1726 | 0.260 |
Why?
|
| Steroids | 4 | 2021 | 372 | 0.260 |
Why?
|
| Benzoates | 2 | 2024 | 128 | 0.250 |
Why?
|
| Chromosomes, Human, Pair 14 | 2 | 2019 | 287 | 0.250 |
Why?
|
| Heterocyclic Compounds | 3 | 2015 | 117 | 0.240 |
Why?
|
| Azacitidine | 3 | 2024 | 1218 | 0.240 |
Why?
|
| Myeloproliferative Disorders | 2 | 2023 | 882 | 0.240 |
Why?
|
| Lymphocyte Activation | 6 | 2016 | 1723 | 0.240 |
Why?
|
| Hydrazines | 2 | 2024 | 213 | 0.240 |
Why?
|
| Cytokines | 4 | 2017 | 2826 | 0.240 |
Why?
|
| Craniospinal Irradiation | 2 | 2017 | 132 | 0.240 |
Why?
|
| Red-Cell Aplasia, Pure | 2 | 2016 | 50 | 0.240 |
Why?
|
| Dose-Response Relationship, Drug | 8 | 2018 | 5071 | 0.230 |
Why?
|
| ABO Blood-Group System | 2 | 2016 | 125 | 0.230 |
Why?
|
| Prospective Studies | 15 | 2024 | 13424 | 0.230 |
Why?
|
| T-Lymphocytes, Cytotoxic | 3 | 2021 | 1020 | 0.230 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 4 | 2020 | 2486 | 0.220 |
Why?
|
| Thiazoles | 4 | 2014 | 723 | 0.220 |
Why?
|
| Toxoplasmosis | 1 | 2024 | 49 | 0.220 |
Why?
|
| Neutrophils | 4 | 2017 | 873 | 0.220 |
Why?
|
| Clinical Trials as Topic | 8 | 2019 | 3846 | 0.220 |
Why?
|
| Primary Myelofibrosis | 2 | 2023 | 914 | 0.220 |
Why?
|
| Genetic Vectors | 4 | 2020 | 1857 | 0.220 |
Why?
|
| Methotrexate | 7 | 2023 | 1025 | 0.210 |
Why?
|
| Photopheresis | 2 | 2021 | 79 | 0.210 |
Why?
|
| Electroporation | 6 | 2013 | 127 | 0.210 |
Why?
|
| In Situ Hybridization, Fluorescence | 6 | 2023 | 2313 | 0.200 |
Why?
|
| Lymphocyte Transfusion | 3 | 2017 | 174 | 0.200 |
Why?
|
| Gene Transfer Techniques | 5 | 2017 | 804 | 0.200 |
Why?
|
| Infusions, Intravenous | 4 | 2013 | 1437 | 0.200 |
Why?
|
| Pyrimidines | 7 | 2014 | 3671 | 0.200 |
Why?
|
| Killer Cells, Natural | 4 | 2024 | 965 | 0.200 |
Why?
|
| Thalidomide | 3 | 2016 | 597 | 0.190 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2024 | 186 | 0.190 |
Why?
|
| Disease Management | 2 | 2018 | 1092 | 0.190 |
Why?
|
| Immune Reconstitution | 1 | 2021 | 25 | 0.190 |
Why?
|
| Polyethylene Glycols | 2 | 2024 | 654 | 0.190 |
Why?
|
| Severity of Illness Index | 6 | 2023 | 4379 | 0.190 |
Why?
|
| Gene Rearrangement | 2 | 2023 | 813 | 0.190 |
Why?
|
| Hematopoietic Stem Cells | 3 | 2015 | 1367 | 0.190 |
Why?
|
| Recombinant Fusion Proteins | 5 | 2016 | 1642 | 0.190 |
Why?
|
| Vascularized Composite Allotransplantation | 1 | 2021 | 29 | 0.190 |
Why?
|
| Hemorrhagic Disorders | 1 | 2021 | 52 | 0.190 |
Why?
|
| Retreatment | 3 | 2016 | 448 | 0.180 |
Why?
|
| Pentostatin | 2 | 2017 | 121 | 0.180 |
Why?
|
| Transfusion Reaction | 1 | 2021 | 101 | 0.180 |
Why?
|
| Interleukin-15 | 2 | 2024 | 190 | 0.180 |
Why?
|
| Blood Platelets | 3 | 2015 | 677 | 0.180 |
Why?
|
| Neoplasm Staging | 7 | 2024 | 14013 | 0.180 |
Why?
|
| Practice Guidelines as Topic | 4 | 2019 | 2401 | 0.170 |
Why?
|
| Bone Marrow Cells | 1 | 2004 | 968 | 0.170 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2020 | 49 | 0.170 |
Why?
|
| Neoplasms, Second Primary | 3 | 2022 | 1388 | 0.170 |
Why?
|
| Gastrointestinal Diseases | 3 | 2024 | 608 | 0.170 |
Why?
|
| Dasatinib | 5 | 2015 | 881 | 0.170 |
Why?
|
| Aniline Compounds | 1 | 2021 | 206 | 0.170 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2024 | 1471 | 0.170 |
Why?
|
| CD3 Complex | 4 | 2013 | 320 | 0.170 |
Why?
|
| Cytarabine | 8 | 2019 | 2014 | 0.160 |
Why?
|
| CD28 Antigens | 4 | 2013 | 203 | 0.160 |
Why?
|
| HLA-DP Antigens | 1 | 2019 | 20 | 0.160 |
Why?
|
| Feasibility Studies | 5 | 2023 | 2364 | 0.160 |
Why?
|
| Cause of Death | 3 | 2017 | 789 | 0.160 |
Why?
|
| Frailty | 1 | 2021 | 133 | 0.160 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 2 | 3 | 2017 | 59 | 0.160 |
Why?
|
| POEMS Syndrome | 1 | 2018 | 23 | 0.160 |
Why?
|
| Lymphocytes | 2 | 2022 | 1275 | 0.160 |
Why?
|
| Anticoagulants | 2 | 2022 | 775 | 0.160 |
Why?
|
| History, 21st Century | 1 | 2020 | 419 | 0.160 |
Why?
|
| Haplotypes | 3 | 2018 | 910 | 0.160 |
Why?
|
| Plasmids | 3 | 2016 | 936 | 0.160 |
Why?
|
| Ehrlichia chaffeensis | 1 | 2018 | 10 | 0.160 |
Why?
|
| Kaplan-Meier Estimate | 9 | 2019 | 6257 | 0.160 |
Why?
|
| Ehrlichiosis | 1 | 2018 | 18 | 0.150 |
Why?
|
| Pulmonary Embolism | 1 | 2022 | 342 | 0.150 |
Why?
|
| Graft Enhancement, Immunologic | 2 | 2015 | 38 | 0.150 |
Why?
|
| Thymus Neoplasms | 1 | 2023 | 416 | 0.150 |
Why?
|
| Frail Elderly | 2 | 2021 | 124 | 0.150 |
Why?
|
| Prednisone | 2 | 2018 | 1034 | 0.150 |
Why?
|
| Cytomegalovirus | 2 | 2019 | 496 | 0.150 |
Why?
|
| Blast Crisis | 1 | 2021 | 588 | 0.150 |
Why?
|
| Acute Lung Injury | 1 | 2019 | 92 | 0.150 |
Why?
|
| HLA-DRB1 Chains | 1 | 2018 | 89 | 0.150 |
Why?
|
| Time Factors | 10 | 2020 | 13024 | 0.150 |
Why?
|
| Tumor Lysis Syndrome | 1 | 2018 | 40 | 0.150 |
Why?
|
| Quinolines | 1 | 2021 | 403 | 0.150 |
Why?
|
| Proportional Hazards Models | 7 | 2023 | 5102 | 0.150 |
Why?
|
| Pyrazoles | 2 | 2024 | 1546 | 0.150 |
Why?
|
| Drug Administration Schedule | 9 | 2018 | 3531 | 0.150 |
Why?
|
| Transgenes | 2 | 2017 | 576 | 0.150 |
Why?
|
| Geriatric Assessment | 2 | 2021 | 290 | 0.140 |
Why?
|
| Febrile Neutropenia | 1 | 2018 | 74 | 0.140 |
Why?
|
| Consolidation Chemotherapy | 1 | 2017 | 153 | 0.140 |
Why?
|
| Graft Rejection | 3 | 2018 | 847 | 0.140 |
Why?
|
| Exotoxins | 1 | 2017 | 76 | 0.140 |
Why?
|
| Mortality | 2 | 2018 | 347 | 0.140 |
Why?
|
| Virus Activation | 1 | 2019 | 237 | 0.140 |
Why?
|
| Propensity Score | 4 | 2021 | 773 | 0.140 |
Why?
|
| Neutropenia | 1 | 2021 | 1006 | 0.140 |
Why?
|
| Chimerism | 1 | 2017 | 65 | 0.140 |
Why?
|
| Bayes Theorem | 3 | 2022 | 1061 | 0.140 |
Why?
|
| Administration, Intravenous | 1 | 2017 | 248 | 0.140 |
Why?
|
| Preoperative Period | 2 | 2017 | 347 | 0.140 |
Why?
|
| Body Fluids | 1 | 2017 | 121 | 0.140 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2017 | 88 | 0.140 |
Why?
|
| Nitriles | 1 | 2021 | 939 | 0.130 |
Why?
|
| Leukemia, Biphenotypic, Acute | 1 | 2016 | 49 | 0.130 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2016 | 68 | 0.130 |
Why?
|
| Receptors, KIR | 1 | 2016 | 64 | 0.130 |
Why?
|
| Secondary Prevention | 2 | 2021 | 311 | 0.130 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2021 | 625 | 0.130 |
Why?
|
| Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | 1 | 2016 | 121 | 0.130 |
Why?
|
| Bacterial Toxins | 1 | 2017 | 229 | 0.130 |
Why?
|
| Cryptococcosis | 1 | 2016 | 69 | 0.130 |
Why?
|
| Edema | 1 | 2017 | 263 | 0.130 |
Why?
|
| Cytogenetic Analysis | 5 | 2020 | 574 | 0.130 |
Why?
|
| Simplexvirus | 1 | 2016 | 180 | 0.130 |
Why?
|
| Skin Neoplasms | 2 | 2023 | 4895 | 0.130 |
Why?
|
| Cytodiagnosis | 1 | 2016 | 201 | 0.130 |
Why?
|
| Thrombocytopenia | 1 | 2021 | 870 | 0.130 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2019 | 285 | 0.130 |
Why?
|
| Pancytopenia | 1 | 2016 | 119 | 0.130 |
Why?
|
| Sequence Analysis, DNA | 1 | 2023 | 2573 | 0.120 |
Why?
|
| Liver Failure, Acute | 1 | 2016 | 99 | 0.120 |
Why?
|
| Fucose | 1 | 2015 | 58 | 0.120 |
Why?
|
| Immunotoxins | 1 | 2015 | 120 | 0.120 |
Why?
|
| Bortezomib | 3 | 2022 | 549 | 0.120 |
Why?
|
| Gastrointestinal Tract | 1 | 2017 | 324 | 0.120 |
Why?
|
| Blood Transfusion | 1 | 2018 | 581 | 0.120 |
Why?
|
| K562 Cells | 5 | 2013 | 345 | 0.120 |
Why?
|
| Drug Monitoring | 1 | 2016 | 352 | 0.120 |
Why?
|
| Liver | 3 | 2024 | 3088 | 0.120 |
Why?
|
| Risk Assessment | 6 | 2024 | 6772 | 0.120 |
Why?
|
| Leukemia, Myeloid | 2 | 2010 | 993 | 0.120 |
Why?
|
| Weight Gain | 1 | 2017 | 472 | 0.120 |
Why?
|
| Genetic Engineering | 2 | 2014 | 295 | 0.110 |
Why?
|
| Cranial Nerve Diseases | 1 | 2014 | 77 | 0.110 |
Why?
|
| Blood Preservation | 1 | 2014 | 60 | 0.110 |
Why?
|
| Cohort Studies | 8 | 2024 | 9479 | 0.110 |
Why?
|
| Granulocyte Precursor Cells | 1 | 2013 | 36 | 0.110 |
Why?
|
| Carmustine | 3 | 2019 | 225 | 0.110 |
Why?
|
| Recombinant Proteins | 5 | 2012 | 3029 | 0.110 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2016 | 593 | 0.110 |
Why?
|
| Alopecia Areata | 1 | 2014 | 58 | 0.110 |
Why?
|
| Deoxyribonucleases | 1 | 2013 | 55 | 0.110 |
Why?
|
| Piperazines | 4 | 2013 | 2145 | 0.110 |
Why?
|
| Neoplasms, Experimental | 1 | 2016 | 784 | 0.110 |
Why?
|
| Patient Readmission | 1 | 2017 | 572 | 0.110 |
Why?
|
| Tissue Engineering | 1 | 2015 | 255 | 0.110 |
Why?
|
| Disability Evaluation | 1 | 2014 | 237 | 0.110 |
Why?
|
| Homologous Recombination | 1 | 2014 | 187 | 0.100 |
Why?
|
| Adenoviridae Infections | 1 | 2013 | 114 | 0.100 |
Why?
|
| Fertility Preservation | 1 | 2014 | 151 | 0.100 |
Why?
|
| Leukemia, B-Cell | 1 | 2013 | 114 | 0.100 |
Why?
|
| Multivariate Analysis | 5 | 2017 | 4329 | 0.100 |
Why?
|
| Blood Donors | 2 | 2010 | 173 | 0.100 |
Why?
|
| Cells, Cultured | 5 | 2013 | 5698 | 0.100 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2013 | 247 | 0.100 |
Why?
|
| Postoperative Period | 1 | 2014 | 667 | 0.100 |
Why?
|
| Transplantation Immunology | 3 | 2019 | 107 | 0.100 |
Why?
|
| Immunoconjugates | 1 | 2015 | 314 | 0.100 |
Why?
|
| Patient Reported Outcome Measures | 3 | 2023 | 864 | 0.100 |
Why?
|
| Social Support | 1 | 2014 | 590 | 0.090 |
Why?
|
| Alleles | 2 | 2015 | 2602 | 0.090 |
Why?
|
| Sample Size | 1 | 2012 | 213 | 0.090 |
Why?
|
| Animals | 13 | 2024 | 62063 | 0.090 |
Why?
|
| Antineoplastic Agents, Immunological | 4 | 2024 | 1335 | 0.090 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2016 | 1269 | 0.090 |
Why?
|
| Aminoglycosides | 2 | 2012 | 233 | 0.090 |
Why?
|
| Patient Safety | 1 | 2016 | 613 | 0.090 |
Why?
|
| Drug Resistance, Neoplasm | 6 | 2018 | 5409 | 0.090 |
Why?
|
| Clonal Anergy | 1 | 2010 | 12 | 0.090 |
Why?
|
| Hepatitis C | 1 | 2016 | 549 | 0.090 |
Why?
|
| Treatment Failure | 4 | 2017 | 1430 | 0.090 |
Why?
|
| Texas | 4 | 2017 | 6450 | 0.090 |
Why?
|
| Benzenesulfonates | 1 | 2011 | 196 | 0.090 |
Why?
|
| Plasma Cells | 2 | 2023 | 197 | 0.090 |
Why?
|
| Vitamin D Deficiency | 1 | 2011 | 121 | 0.090 |
Why?
|
| Patient Selection | 1 | 2017 | 2026 | 0.090 |
Why?
|
| Genotype | 2 | 2016 | 4255 | 0.090 |
Why?
|
| Leukapheresis | 3 | 2022 | 166 | 0.090 |
Why?
|
| Cardiovascular Diseases | 1 | 2023 | 2224 | 0.090 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2015 | 1052 | 0.090 |
Why?
|
| Interleukin-12 | 1 | 2011 | 267 | 0.090 |
Why?
|
| Adaptation, Psychological | 1 | 2014 | 787 | 0.080 |
Why?
|
| Chi-Square Distribution | 2 | 2017 | 1313 | 0.080 |
Why?
|
| Genes, MHC Class I | 1 | 2009 | 50 | 0.080 |
Why?
|
| Epitopes | 1 | 2012 | 707 | 0.080 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2024 | 216 | 0.080 |
Why?
|
| Immune Tolerance | 1 | 2012 | 427 | 0.080 |
Why?
|
| Vaccines | 1 | 2014 | 399 | 0.080 |
Why?
|
| Osteoporosis | 1 | 2011 | 232 | 0.080 |
Why?
|
| Vitamin D | 1 | 2011 | 261 | 0.080 |
Why?
|
| Comorbidity | 3 | 2023 | 2394 | 0.080 |
Why?
|
| Tumor Microenvironment | 1 | 2020 | 3035 | 0.080 |
Why?
|
| Etoposide | 3 | 2018 | 907 | 0.080 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2012 | 622 | 0.080 |
Why?
|
| Benzylamines | 3 | 2015 | 98 | 0.080 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2013 | 481 | 0.080 |
Why?
|
| Endpoint Determination | 1 | 2009 | 180 | 0.080 |
Why?
|
| Vaccination | 1 | 2014 | 1166 | 0.080 |
Why?
|
| Acute Kidney Injury | 1 | 2016 | 761 | 0.080 |
Why?
|
| Cyclosporine | 1 | 2009 | 292 | 0.080 |
Why?
|
| Heart Diseases | 1 | 2014 | 724 | 0.080 |
Why?
|
| Ferritins | 2 | 2021 | 156 | 0.070 |
Why?
|
| Blood Component Removal | 1 | 2008 | 119 | 0.070 |
Why?
|
| Flow Cytometry | 4 | 2016 | 3045 | 0.070 |
Why?
|
| Chronic Disease | 2 | 2023 | 1830 | 0.070 |
Why?
|
| Mice | 7 | 2024 | 35608 | 0.070 |
Why?
|
| Hematopoiesis | 1 | 2011 | 602 | 0.070 |
Why?
|
| Delivery of Health Care | 1 | 2014 | 857 | 0.070 |
Why?
|
| Head and Neck Neoplasms | 1 | 2023 | 4147 | 0.070 |
Why?
|
| Disease Progression | 5 | 2024 | 6868 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2008 | 878 | 0.070 |
Why?
|
| Quality of Life | 4 | 2023 | 4778 | 0.070 |
Why?
|
| Stromal Cells | 1 | 2011 | 826 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2012 | 2655 | 0.070 |
Why?
|
| Lymphoma, Follicular | 1 | 2012 | 636 | 0.070 |
Why?
|
| Positron-Emission Tomography | 2 | 2022 | 2197 | 0.070 |
Why?
|
| Cell Culture Techniques | 3 | 2014 | 575 | 0.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2014 | 1235 | 0.070 |
Why?
|
| Genes, Transgenic, Suicide | 2 | 2017 | 63 | 0.070 |
Why?
|
| Dendritic Cells | 2 | 2023 | 1110 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2007 | 354 | 0.070 |
Why?
|
| Melanoma | 1 | 2023 | 5595 | 0.070 |
Why?
|
| United States | 6 | 2023 | 15868 | 0.060 |
Why?
|
| Coculture Techniques | 3 | 2013 | 628 | 0.060 |
Why?
|
| Monosomy | 2 | 2017 | 98 | 0.060 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2018 | 3658 | 0.060 |
Why?
|
| Antilymphocyte Serum | 3 | 2012 | 237 | 0.060 |
Why?
|
| Imatinib Mesylate | 4 | 2013 | 1691 | 0.060 |
Why?
|
| Cell Lineage | 2 | 2011 | 701 | 0.060 |
Why?
|
| Deoxycytidine | 3 | 2018 | 1389 | 0.060 |
Why?
|
| Minnesota | 1 | 2024 | 126 | 0.060 |
Why?
|
| Fatal Outcome | 2 | 2016 | 824 | 0.060 |
Why?
|
| Pyridines | 1 | 2011 | 1313 | 0.060 |
Why?
|
| Benzamides | 4 | 2013 | 1879 | 0.060 |
Why?
|
| Statistics, Nonparametric | 1 | 2006 | 986 | 0.060 |
Why?
|
| Transplantation Chimera | 2 | 2015 | 174 | 0.060 |
Why?
|
| Alkylating Agents | 1 | 2024 | 81 | 0.060 |
Why?
|
| Tandem Repeat Sequences | 1 | 2024 | 203 | 0.060 |
Why?
|
| Filgrastim | 3 | 2009 | 194 | 0.060 |
Why?
|
| Europe | 2 | 2015 | 659 | 0.060 |
Why?
|
| Mutant Chimeric Proteins | 2 | 2013 | 25 | 0.060 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2023 | 2359 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2021 | 2849 | 0.050 |
Why?
|
| Societies, Medical | 2 | 2019 | 1321 | 0.050 |
Why?
|
| Autografts | 1 | 2023 | 180 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2023 | 3604 | 0.050 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2024 | 201 | 0.050 |
Why?
|
| Chromosome Deletion | 1 | 2007 | 1049 | 0.050 |
Why?
|
| Polyamines | 1 | 2022 | 80 | 0.050 |
Why?
|
| HLA-A Antigens | 1 | 2023 | 105 | 0.050 |
Why?
|
| HLA-A2 Antigen | 1 | 2023 | 172 | 0.050 |
Why?
|
| Cytoskeletal Proteins | 2 | 1995 | 522 | 0.050 |
Why?
|
| Cytological Techniques | 1 | 2002 | 69 | 0.050 |
Why?
|
| Risk | 2 | 2017 | 1940 | 0.050 |
Why?
|
| Gene Duplication | 1 | 2024 | 442 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2023 | 4502 | 0.050 |
Why?
|
| Certification | 1 | 2023 | 107 | 0.050 |
Why?
|
| Zinc Fingers | 2 | 2013 | 222 | 0.050 |
Why?
|
| Cost of Illness | 1 | 2005 | 505 | 0.050 |
Why?
|
| Predictive Value of Tests | 3 | 2017 | 4965 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 3 | 2017 | 3479 | 0.050 |
Why?
|
| Mutation | 4 | 2018 | 15915 | 0.050 |
Why?
|
| Adoptive Transfer | 2 | 2014 | 431 | 0.050 |
Why?
|
| Transfusion-Related Acute Lung Injury | 1 | 2021 | 9 | 0.050 |
Why?
|
| Biopsy | 2 | 2020 | 3485 | 0.050 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2022 | 1260 | 0.050 |
Why?
|
| Lower Gastrointestinal Tract | 1 | 2020 | 29 | 0.050 |
Why?
|
| Injections, Intravenous | 2 | 2012 | 591 | 0.050 |
Why?
|
| Thiotepa | 2 | 2012 | 132 | 0.050 |
Why?
|
| Polydeoxyribonucleotides | 1 | 2019 | 8 | 0.040 |
Why?
|
| Germinal Center | 1 | 2021 | 167 | 0.040 |
Why?
|
| Leukocyte Count | 2 | 2015 | 735 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 7665 | 0.040 |
Why?
|
| Karyotyping | 2 | 2012 | 1063 | 0.040 |
Why?
|
| Cholagogues and Choleretics | 1 | 2019 | 38 | 0.040 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2019 | 55 | 0.040 |
Why?
|
| Oligopeptides | 1 | 2022 | 450 | 0.040 |
Why?
|
| Cell Line, Tumor | 5 | 2015 | 14853 | 0.040 |
Why?
|
| Genes, abl | 1 | 2019 | 119 | 0.040 |
Why?
|
| Podophyllotoxin | 1 | 2019 | 66 | 0.040 |
Why?
|
| Mothers | 1 | 2022 | 416 | 0.040 |
Why?
|
| Butyrophenones | 1 | 2019 | 13 | 0.040 |
Why?
|
| Retroviridae | 1 | 2020 | 373 | 0.040 |
Why?
|
| Ascites | 1 | 2020 | 213 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2024 | 2058 | 0.040 |
Why?
|
| Plasmapheresis | 1 | 2018 | 51 | 0.040 |
Why?
|
| Chromosomes | 1 | 2019 | 325 | 0.040 |
Why?
|
| Age of Onset | 1 | 2021 | 853 | 0.040 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2002 | 1126 | 0.040 |
Why?
|
| Bilirubin | 1 | 2019 | 226 | 0.040 |
Why?
|
| Ultrasonography, Doppler | 1 | 2019 | 275 | 0.040 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2018 | 1302 | 0.040 |
Why?
|
| Protein Domains | 1 | 2019 | 323 | 0.040 |
Why?
|
| Consensus | 1 | 2023 | 1106 | 0.040 |
Why?
|
| Psychometrics | 1 | 2023 | 973 | 0.040 |
Why?
|
| Drug Approval | 1 | 2018 | 174 | 0.040 |
Why?
|
| Clonal Evolution | 1 | 2019 | 250 | 0.040 |
Why?
|
| Critical Pathways | 1 | 2018 | 160 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2011 | 7389 | 0.040 |
Why?
|
| Fibrinolytic Agents | 1 | 2019 | 293 | 0.040 |
Why?
|
| Anemia, Refractory, with Excess of Blasts | 1 | 2017 | 88 | 0.040 |
Why?
|
| Precursor Cells, T-Lymphoid | 1 | 2016 | 23 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2018 | 574 | 0.030 |
Why?
|
| Patient Comfort | 1 | 2016 | 7 | 0.030 |
Why?
|
| Foscarnet | 1 | 2016 | 19 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2023 | 1567 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2002 | 2474 | 0.030 |
Why?
|
| Point Mutation | 1 | 2019 | 788 | 0.030 |
Why?
|
| Epidemiologic Methods | 1 | 2017 | 254 | 0.030 |
Why?
|
| Calcineurin Inhibitors | 1 | 2017 | 67 | 0.030 |
Why?
|
| Drug Evaluation | 1 | 2016 | 432 | 0.030 |
Why?
|
| Acyclovir | 1 | 2016 | 79 | 0.030 |
Why?
|
| Transaminases | 1 | 2016 | 82 | 0.030 |
Why?
|
| Bone Marrow Examination | 1 | 2016 | 150 | 0.030 |
Why?
|
| Drug Resistance, Viral | 1 | 2016 | 70 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2017 | 418 | 0.030 |
Why?
|
| Transplant Recipients | 1 | 2019 | 337 | 0.030 |
Why?
|
| Biomarkers | 2 | 2019 | 5063 | 0.030 |
Why?
|
| Valine | 1 | 2016 | 180 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2016 | 164 | 0.030 |
Why?
|
| Proteasome Inhibitors | 1 | 2017 | 235 | 0.030 |
Why?
|
| Methylprednisolone | 1 | 2016 | 198 | 0.030 |
Why?
|
| Rhodamines | 1 | 2015 | 48 | 0.030 |
Why?
|
| Dacarbazine | 1 | 2018 | 502 | 0.030 |
Why?
|
| Intercellular Junctions | 1 | 1995 | 56 | 0.030 |
Why?
|
| Histocompatibility Antigens | 1 | 2015 | 79 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2023 | 1656 | 0.030 |
Why?
|
| Aftercare | 1 | 2017 | 252 | 0.030 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2016 | 65 | 0.030 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2017 | 375 | 0.030 |
Why?
|
| Fatigue | 1 | 2021 | 1278 | 0.030 |
Why?
|
| Facial Nerve Diseases | 1 | 2014 | 21 | 0.030 |
Why?
|
| Gene Editing | 1 | 2017 | 229 | 0.030 |
Why?
|
| Fucosyltransferases | 1 | 2015 | 78 | 0.030 |
Why?
|
| Photosensitizing Agents | 1 | 2015 | 82 | 0.030 |
Why?
|
| E-Selectin | 1 | 2015 | 106 | 0.030 |
Why?
|
| Granzymes | 1 | 2015 | 94 | 0.030 |
Why?
|
| Kidney | 1 | 2023 | 2122 | 0.030 |
Why?
|
| P-Selectin | 1 | 2015 | 110 | 0.030 |
Why?
|
| Infant | 3 | 2015 | 14006 | 0.030 |
Why?
|
| Hominidae | 1 | 1994 | 43 | 0.030 |
Why?
|
| Living Donors | 1 | 2015 | 175 | 0.030 |
Why?
|
| Platelet Transfusion | 1 | 2015 | 166 | 0.030 |
Why?
|
| Syndrome | 1 | 2017 | 1407 | 0.030 |
Why?
|
| Protons | 1 | 2017 | 482 | 0.030 |
Why?
|
| Transcriptome | 1 | 2023 | 1962 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 1823 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2024 | 6239 | 0.030 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2016 | 334 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2019 | 1193 | 0.030 |
Why?
|
| Brain Diseases | 1 | 2017 | 412 | 0.030 |
Why?
|
| RNA, Messenger | 3 | 2013 | 6398 | 0.030 |
Why?
|
| Viral Load | 1 | 2016 | 485 | 0.030 |
Why?
|
| Photons | 1 | 2017 | 536 | 0.030 |
Why?
|
| Guinea Pigs | 1 | 2013 | 252 | 0.030 |
Why?
|
| Immunocompromised Host | 1 | 2018 | 720 | 0.030 |
Why?
|
| Optic Nerve Diseases | 1 | 2014 | 111 | 0.030 |
Why?
|
| Cytogenetics | 1 | 2013 | 152 | 0.030 |
Why?
|
| Nervous System Diseases | 1 | 2017 | 517 | 0.030 |
Why?
|
| Induction Chemotherapy | 1 | 2016 | 670 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2016 | 451 | 0.030 |
Why?
|
| DNA, Superhelical | 1 | 2013 | 28 | 0.030 |
Why?
|
| Protein Engineering | 1 | 2013 | 100 | 0.030 |
Why?
|
| Hepacivirus | 1 | 2016 | 423 | 0.030 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 1 | 2017 | 460 | 0.030 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2014 | 228 | 0.030 |
Why?
|
| Blood Cell Count | 1 | 2012 | 233 | 0.030 |
Why?
|
| Actins | 1 | 1995 | 602 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2023 | 6195 | 0.030 |
Why?
|
| Cell Count | 1 | 2013 | 513 | 0.030 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2013 | 244 | 0.030 |
Why?
|
| Liver Diseases | 1 | 2017 | 602 | 0.030 |
Why?
|
| Enediynes | 1 | 2012 | 13 | 0.030 |
Why?
|
| Data Collection | 1 | 2014 | 608 | 0.030 |
Why?
|
| Antigen Presentation | 1 | 2013 | 286 | 0.020 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2012 | 172 | 0.020 |
Why?
|
| Sex Factors | 1 | 2017 | 2185 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2023 | 3440 | 0.020 |
Why?
|
| Mucositis | 1 | 2012 | 149 | 0.020 |
Why?
|
| Radioimmunotherapy | 1 | 2012 | 128 | 0.020 |
Why?
|
| L-Selectin | 1 | 2011 | 36 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2012 | 655 | 0.020 |
Why?
|
| Cadherins | 1 | 1994 | 657 | 0.020 |
Why?
|
| Gene Knockout Techniques | 1 | 2012 | 269 | 0.020 |
Why?
|
| Alternative Splicing | 1 | 1994 | 611 | 0.020 |
Why?
|
| Endonucleases | 1 | 2012 | 184 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2023 | 3346 | 0.020 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2013 | 683 | 0.020 |
Why?
|
| Embryonic Stem Cells | 1 | 2013 | 278 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2016 | 2271 | 0.020 |
Why?
|
| Serum Albumin | 1 | 2011 | 246 | 0.020 |
Why?
|
| Parathyroid Hormone | 1 | 2011 | 184 | 0.020 |
Why?
|
| Glioblastoma | 2 | 2013 | 1776 | 0.020 |
Why?
|
| Transplantation | 1 | 2010 | 57 | 0.020 |
Why?
|
| Yttrium Radioisotopes | 1 | 2012 | 210 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2014 | 2320 | 0.020 |
Why?
|
| Lymphocyte Count | 1 | 2012 | 485 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2013 | 714 | 0.020 |
Why?
|
| Cell Line | 2 | 2015 | 5339 | 0.020 |
Why?
|
| Demography | 1 | 2011 | 433 | 0.020 |
Why?
|
| Base Sequence | 2 | 2013 | 5437 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 1995 | 1309 | 0.020 |
Why?
|
| Catalytic Domain | 1 | 2010 | 305 | 0.020 |
Why?
|
| Niacinamide | 1 | 2011 | 428 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 2013 | 889 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 1199 | 0.020 |
Why?
|
| Molecular Sequence Data | 2 | 2013 | 6686 | 0.020 |
Why?
|
| Biomarkers, Tumor | 2 | 2020 | 10709 | 0.020 |
Why?
|
| Cell Proliferation | 2 | 2013 | 7239 | 0.020 |
Why?
|
| Rabbits | 1 | 2010 | 1028 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2013 | 1462 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2011 | 897 | 0.020 |
Why?
|
| Herpesvirus 4, Human | 1 | 2013 | 961 | 0.020 |
Why?
|
| Interleukins | 1 | 2011 | 341 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2012 | 1610 | 0.020 |
Why?
|
| Bone Density | 1 | 2011 | 467 | 0.020 |
Why?
|
| Gallium Radioisotopes | 1 | 2008 | 62 | 0.020 |
Why?
|
| Graft vs Leukemia Effect | 1 | 2009 | 107 | 0.020 |
Why?
|
| Ifosfamide | 1 | 2009 | 358 | 0.020 |
Why?
|
| Prevalence | 1 | 2016 | 3404 | 0.020 |
Why?
|
| Phenylurea Compounds | 1 | 2011 | 600 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2013 | 1497 | 0.020 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2007 | 144 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2010 | 1472 | 0.020 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 3 | 1 | 2007 | 95 | 0.020 |
Why?
|
| Whole Body Imaging | 1 | 2008 | 120 | 0.020 |
Why?
|
| Cell Movement | 1 | 2015 | 2474 | 0.020 |
Why?
|
| Leukemic Infiltration | 1 | 2007 | 73 | 0.020 |
Why?
|
| Logistic Models | 1 | 2014 | 3448 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2010 | 1360 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2011 | 1180 | 0.020 |
Why?
|
| Atrial Fibrillation | 1 | 2014 | 730 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 1994 | 3341 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2012 | 1570 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2016 | 12108 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2006 | 342 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2009 | 1571 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2012 | 1185 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2007 | 558 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 5171 | 0.020 |
Why?
|
| alpha Catenin | 2 | 1995 | 24 | 0.020 |
Why?
|
| Calcium | 1 | 2011 | 1589 | 0.020 |
Why?
|
| Cranial Irradiation | 1 | 2007 | 322 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 3187 | 0.020 |
Why?
|
| Gene Expression | 1 | 2013 | 3643 | 0.020 |
Why?
|
| Central Nervous System | 1 | 2007 | 453 | 0.020 |
Why?
|
| STAT3 Transcription Factor | 1 | 2011 | 1136 | 0.010 |
Why?
|
| DNA Methylation | 1 | 2014 | 2767 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2007 | 1419 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 2008 | 1341 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2013 | 4117 | 0.010 |
Why?
|
| Survivors | 1 | 2007 | 1023 | 0.010 |
Why?
|
| Algorithms | 1 | 2012 | 3900 | 0.010 |
Why?
|
| Medical Oncology | 1 | 2009 | 1465 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2009 | 2453 | 0.010 |
Why?
|
| Cell Compartmentation | 1 | 1995 | 86 | 0.010 |
Why?
|
| Palliative Care | 1 | 2007 | 2178 | 0.010 |
Why?
|
| Chickens | 1 | 1994 | 783 | 0.010 |
Why?
|
| Dogs | 1 | 1995 | 1160 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 1995 | 979 | 0.010 |
Why?
|
| Conserved Sequence | 1 | 1994 | 498 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1995 | 1121 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1994 | 938 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1994 | 1082 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1994 | 1431 | 0.010 |
Why?
|
| Phylogeny | 1 | 1994 | 867 | 0.010 |
Why?
|
| Drosophila | 1 | 1994 | 909 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1994 | 4569 | 0.000 |
Why?
|